FORMULATION DEVELOPMENT AND STABILITY INDICATING HPLC ASSAY OF TABLETS OF APIXABAN

Objective: Cost effective formulation development and stability indicating HPLC method for estimation of apixaban in bulk and tablets dosage form.Methods: 32 factorial design was applied to formulate the immediate release tablets of apixaban by using direct compression method. The chromatographic se...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmacy and pharmaceutical sciences Vol. 9; no. 10; p. 24
Main Authors: Jain, Hemant K., Nikam, Vishal K.
Format: Journal Article
Language:English
Published: 02-10-2017
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Objective: Cost effective formulation development and stability indicating HPLC method for estimation of apixaban in bulk and tablets dosage form.Methods: 32 factorial design was applied to formulate the immediate release tablets of apixaban by using direct compression method. The chromatographic separation was performed on Purospher Star RP-18e (5 µm, 250x4, 6 mm) column and a stability indicating assay method was developed by using HPLC. The mobile phase consists of water: acetonitrile (60:40 v/v) was delivered at a flow rate of 1 ml/min and UV detection at 280 nm. The method was validated with forced degradation studies as per ICH guidelines.Results: Prepared batches were evaluated for all pre-compression parameters and post-compression parameters. Formulation batch F5 prepared by direct compression shows highest dissolution release of 90.97 % over the period of 60 min while disintegration time was found to be 136 seconds. The retention time of developed HPLC method was found to be 5.66 min. This method was found to be linear in a concentration range of 5-30 μg/ml of the drug (r2= 0.999). The low value of % RSD in the precision study indicates reproducibility of the method. The low value of LOD and LOQ suggests the sensitivity of the method. The results of forced degradation studies indicated that the drug was less stable in thermal and photolytic condition and degraded in acidic, basic, oxidative conditions.Conclusion: On the basis of formulation evaluation, batch F5 was found to be promising formulation suitable for the immediate release of apixaban. Results obtained by validation studies suggested that the developed stability indicating assay method is simple, accurate, specific, sensitive and precise. Thus, this method can be used for routine analysis of apixaban formulation and to check the stability testing. 
AbstractList Objective: Cost effective formulation development and stability indicating HPLC method for estimation of apixaban in bulk and tablets dosage form.Methods: 32 factorial design was applied to formulate the immediate release tablets of apixaban by using direct compression method. The chromatographic separation was performed on Purospher Star RP-18e (5 µm, 250x4, 6 mm) column and a stability indicating assay method was developed by using HPLC. The mobile phase consists of water: acetonitrile (60:40 v/v) was delivered at a flow rate of 1 ml/min and UV detection at 280 nm. The method was validated with forced degradation studies as per ICH guidelines.Results: Prepared batches were evaluated for all pre-compression parameters and post-compression parameters. Formulation batch F5 prepared by direct compression shows highest dissolution release of 90.97 % over the period of 60 min while disintegration time was found to be 136 seconds. The retention time of developed HPLC method was found to be 5.66 min. This method was found to be linear in a concentration range of 5-30 μg/ml of the drug (r2= 0.999). The low value of % RSD in the precision study indicates reproducibility of the method. The low value of LOD and LOQ suggests the sensitivity of the method. The results of forced degradation studies indicated that the drug was less stable in thermal and photolytic condition and degraded in acidic, basic, oxidative conditions.Conclusion: On the basis of formulation evaluation, batch F5 was found to be promising formulation suitable for the immediate release of apixaban. Results obtained by validation studies suggested that the developed stability indicating assay method is simple, accurate, specific, sensitive and precise. Thus, this method can be used for routine analysis of apixaban formulation and to check the stability testing. 
Author Jain, Hemant K.
Nikam, Vishal K.
Author_xml – sequence: 1
  givenname: Hemant K.
  surname: Jain
  fullname: Jain, Hemant K.
– sequence: 2
  givenname: Vishal K.
  surname: Nikam
  fullname: Nikam, Vishal K.
BookMark eNpNkF9rgzAUxcPoYF3XrzDyBexuEqPmMVXbCmmUasf6JP6JYNlaURjs28-6MXZe7uFyznn4PaLZ5XoxCD0TWFFKuHhpz103rCgQ91O0ty8wm92hOQiXW8QWZPbPP6DlMJxhlA2UAJujwyY-7I9KZlGscRC-hipO9qHOsNQBTjO5jlSUnXCkg8gfQ3qLd4nysUxTecLxBo8JFWbpzcokepNrqZ_QfVO8D2b5exfouAkzf2epeDuOKKsiAMxyKigN46QsPGqKWtCmEi7UQKlgVWm74Jrao43HuQe0KY3DXVKWghub8GJssQVyfnar_joMvWnyrm8_iv4rJ5BPcPIJTv4HJ5_gsG89w1Qf
CitedBy_id crossref_primary_10_1208_s12249_023_02628_2
crossref_primary_10_3390_pharmaceutics15061668
crossref_primary_10_3390_pharmaceutics15010080
crossref_primary_10_1208_s12249_021_02020_y
crossref_primary_10_1039_D3RA03293K
crossref_primary_10_1093_chromsci_bmad065
ContentType Journal Article
DBID AAYXX
CITATION
DOI 10.22159/ijpps.2017v9i10.20343
DatabaseName CrossRef
DatabaseTitle CrossRef
DatabaseTitleList CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 0975-1491
ExternalDocumentID 10_22159_ijpps_2017v9i10_20343
GroupedDBID ---
2WC
53G
5VS
AAYXX
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
CITATION
DIK
GX1
HH5
KQ8
M~E
OK1
P6G
RNS
TR2
ID FETCH-LOGICAL-c1003-6c0be351ba82ead92fc970d02293cb4707ed82f855802fbe6571bb95e415a1ba3
ISSN 0975-1491
IngestDate Thu Nov 21 21:05:14 EST 2024
IsPeerReviewed false
IsScholarly true
Issue 10
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c1003-6c0be351ba82ead92fc970d02293cb4707ed82f855802fbe6571bb95e415a1ba3
ParticipantIDs crossref_primary_10_22159_ijpps_2017v9i10_20343
PublicationCentury 2000
PublicationDate 2017-10-02
PublicationDateYYYYMMDD 2017-10-02
PublicationDate_xml – month: 10
  year: 2017
  text: 2017-10-02
  day: 02
PublicationDecade 2010
PublicationTitle International journal of pharmacy and pharmaceutical sciences
PublicationYear 2017
SSID ssj0000402103
Score 2.1289587
Snippet Objective: Cost effective formulation development and stability indicating HPLC method for estimation of apixaban in bulk and tablets dosage form.Methods: 32...
SourceID crossref
SourceType Aggregation Database
StartPage 24
Title FORMULATION DEVELOPMENT AND STABILITY INDICATING HPLC ASSAY OF TABLETS OF APIXABAN
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxELbScuGCyktAAfmAekmXep-2jxuaklVDiMgWtadVvOuVWtoQ9YHEv2f82LVBEaIHLqvNRB5t8n2yPbPjbxB618Y1oJ7EgZIKhwBF8EDERAQha0gWiZaFS5UamCzo7JQdjpPxYNB1AHO2_4o02ABrdXL2Hmj3TsEA94A5XAF1uP4T7hDVfTqZmmY6XodNLSO1KPNRMS3Ks2ExO9RHiGcfh5P5VLUjXuRnugIoH03HpW5ons-L03xk1V4vXMW7SyB6shNrI4Ft1Jzshy5RbldZV6y4NMIFE3kFuA6P37uXI98MP7-qntCX3Tc2KQELnXql7ucpOU0DCL4MbeQGm518uc8x4s-kyaYJPoIdihJIPb9Yr5XYekh_8HNlJ7FRe_pdUfuPla6vP4TIR3uqtJ-q91NpP1voQQQE1gF6cdxn7GC6g_hYlyx0v8QcOdeuDjY-krfb8bYt5Q56ZOMNnBuiPEYDuXqC9uYWrX1cuvN3N_t4D8-dlPnPp-iLxybssQkDm3DPJuzYhBWbsGYT_nyELZvUbcemZ-jkaFx-mAS2C0dQh6pwMauJkHEaiiWLYNrhUVtzShrY-_G4FgklVDYsalmaMhK1QmYpDYXgqYSt4RJGxc_R9ur7Sr5AOM4Ib-qMs4zWSRvVIpQtZRKGhLVIY_4SHXT_VrU2YivV36F6de8Ru-ihI-xrtH17fSffoK2b5u6thvsXLVhpDA
link.rule.ids 315,782,786,27933,27934
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FORMULATION+DEVELOPMENT+AND+STABILITY+INDICATING+HPLC+ASSAY+OF+TABLETS+OF+APIXABAN&rft.jtitle=International+journal+of+pharmacy+and+pharmaceutical+sciences&rft.au=Jain%2C+Hemant+K.&rft.au=Nikam%2C+Vishal+K.&rft.date=2017-10-02&rft.issn=0975-1491&rft.eissn=0975-1491&rft.volume=9&rft.issue=10&rft.spage=24&rft_id=info:doi/10.22159%2Fijpps.2017v9i10.20343&rft.externalDBID=n%2Fa&rft.externalDocID=10_22159_ijpps_2017v9i10_20343
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0975-1491&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0975-1491&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0975-1491&client=summon